GLP-1 Peptides · SP-029
Retatrutide
10mg · Lyophilized Powder
Triple GIP/GLP-1/Glucagon receptor agonist — the frontier of metabolic research.
CoA Included
Express Ship
Research Grade
Retatrutide is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents the cutting edge of incretin-based research, with studies showing significant effects on body weight, glucose control, and metabolic parameters. As the first triple agonist in its class, Retatrutide opens new frontiers in metabolic research.
Please Note: Retatrutide is supplied in lyophilized powder form and must be reconstituted with bacteriostatic water before research use to ensure proper mixing and stability. For research purposes only.
Related Research
The GLP 1 Market in 2026: Trends, Competition, and What Comes Next
The GLP 1 market has exploded into one of the largest pharmaceutical categories in history. This analysis examines the competitive landscape, emerging compounds, and future directions for 2026 and beyond.
Retatrutide: The Triple Agonist Redefining Metabolic Research
Retatrutide takes the incretin concept further than ever before with triple agonism at GIP, GLP 1, and glucagon receptors. Early research data suggests this could be the most potent metabolic compound ever studied.
What Are Peptides? A Complete Beginner Guide to Peptide Science
Peptides are short chains of amino acids that serve as signalling molecules throughout the body. This comprehensive guide explains what peptides are, how they work, and why they are revolutionising research.
